Maryjane A Farr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7691976/publications.pdf

Version: 2024-02-01

101 3,375 30 54 g-index

102 102 102 5108

102 102 102 5108 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	De Novo Human Leukocyte Antigen Allosensitization in Heartmate 3 Versus Heartmate II Left Ventricular Assist Device Recipients. ASAIO Journal, 2022, 68, 226-232.	1.6	9
2	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clinical Gastroenterology and Hepatology, 2022, 20, 1636-1662.e36.	4.4	95
3	Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. Journal of Heart and Lung Transplantation, 2022, 41, 199-207.	0.6	9
4	Impact of Temporary Percutaneous Mechanical Circulatory Support Before Transplantation in the 2018 Heart Allocation System. JACC: Heart Failure, 2022, 10, 12-23.	4.1	21
5	Impact of UNOS allocation policy changes on utilization and outcomes of patients bridged to heart transplant with intraâ€aortic balloon pump. Clinical Transplantation, 2022, 36, e14533.	1.6	14
6	Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008968.	3.9	4
7	Heart Xenotransplant: A Door That Is Finally Opening. Circulation, 2022, 145, 871-873.	1.6	8
8	Evolving Characteristics of Heart Transplantation Donors and Recipients. Journal of the American College of Cardiology, 2022, 79, 1108-1123.	2.8	16
9	Recovery With Temporary Mechanical Circulatory Support While Waitlisted for Heart Transplantation. Journal of the American College of Cardiology, 2022, 79, 900-913.	2.8	20
10	Impact of socioeconomic deprivation on evaluation for heart transplantation at an urban academic medical center. Clinical Transplantation, 2022, 36, e14652.	1.6	3
11	Increased Opportunities for Transplantation for Women in the New Heart Allocation System. Journal of Cardiac Failure, 2022, 28, 1149-1157.	1.7	12
12	Deep vein thrombosis and pulmonary embolism after heart transplantation. Clinical Transplantation, 2022, 36, e14705.	1.6	2
13	Outcomes of Heart Transplantation in Adult Congenital Heart Disease With Prior Intracardiac Repair. Annals of Thoracic Surgery, 2021, 112, 846-853.	1.3	9
14	T cell repertoire analysis suggests a prominent bystander response in human cardiac allograft vasculopathy. American Journal of Transplantation, 2021, 21, 1465-1476.	4.7	10
15	C-Reactive Protein Levels Predict Outcomes in Continuous-Flow Left Ventricular Assist Device Patients. ASAIO Journal, 2021, Publish Ahead of Print, 884-890.	1.6	4
16	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009203.	4.8	14
17	Cardiac transplantation in adult congenital heart disease with prior sternotomy. Clinical Transplantation, 2021, 35, e14229.	1.6	5
18	Extracorporeal photopheresis and its role in heart transplant rejection: prophylaxis and treatment. Clinical Transplantation, 2021, 35, e14333.	1.6	19

#	Article	IF	CITATIONS
19	Outcomes of COVIDâ€19 in solid organ transplant recipients: A matched cohort study. Transplant Infectious Disease, 2021, 23, e13637.	1.7	47
20	Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection. American Journal of Transplantation, 2021, 21, 2254-2261.	4.7	40
21	Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?. American Heart Journal, 2021, 239, 11-18.	2.7	2
22	Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis. Circulation: Heart Failure, 2021, 14, e007909.	3.9	14
23	Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?. Circulation: Heart Failure, 2021, 14, e007916.	3.9	13
24	A Pioneer in Transplantation Genomics, Inclusion, and Diversity: A Conversation With Hannah Valantine, MBBS, MD. Circulation, 2021, 143, 2321-2326.	1.6	0
25	Transcriptomic heterogeneity of antibody mediated rejection after heart transplant with or without donor specific antibodies. Journal of Heart and Lung Transplantation, 2021, 40, 1472-1480.	0.6	9
26	The Role of Serial Right Heart Catheterization Survey in Patients Awaiting Heart Transplant on Ventricular Assist Device. ASAIO Journal, 2021, Publish Ahead of Print, .	1.6	2
27	Changes in waitlist and posttransplant outcomes in patients with adult congenital heart disease after the new heart transplant allocation system. Clinical Transplantation, 2021, 35, e14458.	1.6	8
28	How can we better inform our patients about postâ€heart transplantation survival? A conditional survival analysis. Clinical Transplantation, 2021, 35, e14449.	1.6	0
29	Chronic intermittent intravenous immunoglobulin in heart transplant recipients with elevated donorâ€specific antibody levels. Clinical Transplantation, 2021, , e14524.	1.6	1
30	A Foot Soldier in Cardiac Metabolism: A Conversation With Heinrich Taegtmeyer, MD, DPhil. Circulation, 2021, 144, 1659-1663.	1.6	0
31	Critically appraising the 2018 United Network for Organ Sharing donor allocation policy. Current Opinion in Anaesthesiology, 2021, Publish Ahead of Print, .	2.0	5
32	Considerations for Referral: What Happens to Patients After Being Turned Down for Left Ventricular Assist Device Therapy. Journal of Cardiac Failure, 2020, 26, 300-307.	1.7	2
33	Potential for donation after circulatory death heart transplantation in the United States: Retrospective analysis of a limited UNOS dataset. American Journal of Transplantation, 2020, 20, 525-529.	4.7	23
34	Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction. Clinical Transplantation, 2020, 34, e13779.	1.6	9
35	Effect of Pulmonary Hypertension on Transplant Outcomes in Patients With Ventricular Assist Devices. Annals of Thoracic Surgery, 2020, 110, 158-164.	1.3	2
36	PCSK9 Inhibitor Use in Heart Transplant Recipients: A Case Series and Review of the Literature. Transplantation, 2020, 104, e38-e39.	1.0	9

#	Article	IF	CITATIONS
37	Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system. Clinical Transplantation, 2020, 34, e14109.	1.6	14
38	Cardiac Implantable Electronic Devices Following Heart Transplantation. JACC: Clinical Electrophysiology, 2020, 6, 1028-1042.	3.2	11
39	Psychosocial Risk and Its Association With Outcomes in Continuous-Flow Left Ventricular Assist Device Patients. Circulation: Heart Failure, 2020, 13, e006910.	3.9	33
40	Outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clinical Transplantation, 2020, 34, e14028.	1.6	15
41	Outcomes of mechanical support for cardiogenic shock associated with late cardiac allograft failure. Journal of Cardiac Surgery, 2020, 35, 3381-3386.	0.7	1
42	Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. American Journal of Transplantation, 2020, 20, 3198-3205.	4.7	48
43	Trends in US Heart Transplant Waitlist Activity and Volume During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Cardiology, 2020, 5, 1048.	6.1	58
44	Transition of a Large Tertiary Heart Failure Program in Response to the COVID-19 Pandemic. Circulation: Heart Failure, 2020, 13, e007516.	3.9	17
45	Minimally invasive central venoarterial extracorporeal membrane oxygenation for long-term ambulatory support as a bridge to heart–lung transplant. Journal of Artificial Organs, 2020, 23, 394-396.	0.9	8
46	Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1165.	6.1	170
47	A change of heart: Preliminary results of the US 2018 adult heart allocation revision. American Journal of Transplantation, 2020, 20, 2781-2790.	4.7	113
48	Gut microbial diversity, inflammation, and oxidative stress are associated with tacrolimus dosing requirements early after heart transplantation. PLoS ONE, 2020, 15, e0233646.	2.5	15
49	Practice Patterns Surrounding Pregnancy After Heart Transplantation. Circulation: Heart Failure, 2020, 13, e006811.	3.9	17
50	Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. American Journal of Transplantation, 2020, 20, 3620-3630.	4.7	27
51	Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant. Journal of Heart and Lung Transplantation, 2020, 39, 880-890.	0.6	65
52	Profiling non-HLA antibody responses in antibody-mediated rejection following heart transplantation. American Journal of Transplantation, 2020, 20, 2571-2580.	4.7	22
53	Impact of Induction Immunosuppression on Post-Transplant Outcomes of Patients Bridged with Contemporary Left Ventricular Assist Devices. ASAIO Journal, 2020, 66, 261-267.	1.6	6
54	Association between recipient blood type and heart transplantation outcomes in the United States. Journal of Heart and Lung Transplantation, 2020, 39, 363-370.	0.6	11

#	Article	IF	CITATIONS
55	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. American Journal of Transplantation, 2020, 20, 1800-1808.	4.7	683
56	Challenges in Heart Transplantation in the Era of COVID-19. Circulation, 2020, 141, 2048-2051.	1.6	47
57	Local competition influences donor heart acceptance practice. Journal of Heart and Lung Transplantation, 2020, 39, 835-838.	0.6	О
58	Heart or lung transplant outcomes in HIV-infected recipients. Journal of Heart and Lung Transplantation, 2019, 38, 1296-1305.	0.6	37
59	Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality. Circulation, 2019, 140, 459-469.	1.6	49
60	Outcomes of bridge to cardiac retransplantation in the contemporary mechanical circulatory support era. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 171-181.e1.	0.8	10
61	Prior Amiodarone Exposure Reduces Tacrolimus Dosing Requirements in Heart Transplant Recipients. Progress in Transplantation, 2019, 29, 129-134.	0.7	4
62	Management of primary graft failure after heart transplantation: Preoperative risks, perioperative events, and postoperative decisions. Clinical Transplantation, 2019, 33, e13557.	1.6	13
63	Extracorporeal membrane oxygenation for primary graft dysfunction after heart transplant. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 1576-1584.e3.	0.8	44
64	Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation. JACC: Heart Failure, 2019, 7, 250-257.	4.1	66
65	Desensitization in the Era of Precision Medicine: Moving From the Bench to Bedside. Transplantation, 2019, 103, 1574-1581.	1.0	8
66	Predictors of Survival for Patients with Acute Decompensated Heart Failure Requiring Extra-Corporeal Membrane Oxygenation Therapy. ASAIO Journal, 2019, 65, 781-787.	1.6	14
67	Advanced Therapies for Advanced Heart Failure in Women. Heart Failure Clinics, 2019, 15, 97-107.	2.1	18
68	A continuous-flow external ventricular assist device for cardiogenic shock: Evolution over 10Âyears. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 157-165.e1.	0.8	21
69	Ventricular Assist Device Utilization in Heart Transplant Candidates. Circulation: Heart Failure, 2018, 11, e004586.	3.9	44
70	Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis. International Journal of Cardiology, 2018, 265, 71-76.	1.7	32
71	Letter by Clerkin et al Regarding Article, "Importance of Routine Antihuman/Leukocyte Antibody Monitoring: De Novo Donor Specific Antibodies Are Associated With Rejection and Allograft Vasculopathy After Heart Transplantation― Circulation, 2018, 137, 1870-1871.	1.6	0
72	Socioeconomic Disparities in Adherence and Outcomes After Heart Transplant. Circulation: Heart Failure, 2018, 11, e004173.	3.9	59

#	Article	IF	CITATIONS
73	Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004665.	3.9	22
74	Incidence and risk factors of groin lymphocele formation after venoarterial extracorporeal membrane oxygenation in cardiogenic shock patients. Journal of Vascular Surgery, 2018, 67, 542-548.	1.1	19
75	Incidence and Impact of On-Cardiopulmonary Bypass Vasoplegia During Heart Transplantation. ASAIO Journal, 2018, 64, 43-51.	1.6	32
76	Impact of Sharing O Heart With Non-O Recipients: Simulation in the United Network for Organ Sharing Registry. Annals of Thoracic Surgery, 2018, 106, 1356-1363.	1.3	3
77	Risk of severe primary graft dysfunction in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2018, 37, 1433-1442.	0.6	49
78	<scp>VA</scp> â€ <scp>ECMO</scp> for cardiogenic shock in the contemporary era of heart transplantation: Which patients should be urgently transplanted?. Clinical Transplantation, 2018, 32, e13356.	1.6	8
79	Improved outcomes from extracorporeal membrane oxygenation versus ventricular assist device temporary support of primary graft dysfunction in heart transplant. Journal of Heart and Lung Transplantation, 2017, 36, 650-656.	0.6	88
80	The new United States heart allocation policy: Progress through collaborative revision. Journal of Heart and Lung Transplantation, 2017, 36, 595-596.	0.6	34
81	Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 862-870.	0.6	36
82	Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 540-545.	0.6	107
83	Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 1226-1233.	0.6	42
84	Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays. Transplantation Direct, 2017, 3, e218.	1.6	25
85	Minimally invasive CentriMag ventricular assist device support integrated with extracorporeal membrane oxygenation in cardiogenic shock patients: a comparison with conventional CentriMag biventricular support configuration. European Journal of Cardio-thoracic Surgery, 2017, 52, 1055-1061.	1.4	48
86	Abstract 21416: Variation Across Centers and Predictors of Initial Immunosuppression Strategy After Heart Transplant. Circulation, 2017, 136, .	1.6	0
87	Abstract 21394: Socioeconomic and Racial Disparities in Outcomes Among Patients Listed for Heart Transplant in the United States. Circulation, 2017, 136, .	1.6	0
88	Abstract 21350: Outcomes With Steroid-Free Maintenance Immunosuppression After Heart Transplant: Results From the United Network for Organ Sharing Registry. Circulation, 2017, 136, .	1.6	0
89	Outcomes of Adult Patients With Congenital Heart Disease After Heart Transplantation: Impact of Disease Type, Previous Thoracic Surgeries, and Bystander Organ Dysfunction. Journal of Cardiac Failure, 2016, 22, 578-582.	1.7	30
90	Infectious complications after cardiac transplantation in patients bridged with mechanical circulatory support devices versus medical therapy. Journal of Heart and Lung Transplantation, 2016, 35, 1116-1123.	0.6	15

#	Article	IF	CITATIONS
91	Vascular inflammation and abnormal aortic histomorphometry in patients after pulsatile- and continuous-flow left ventricular assist device placement. Journal of Heart and Lung Transplantation, 2016, 35, 1085-1091.	0.6	13
92	Dobutamine stress echocardiography is inadequate to detect early cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2016, 35, 1040-1041.	0.6	31
93	Similar Survival in Patients Following Heart Transplantation Receiving Induction Therapy Using Daclizumab vs. Basiliximab. Circulation Journal, 2015, 79, 368-374.	1.6	8
94	Left and Right Ventricular Functional Dynamics Determined by Echocardiograms Before and After Lung Transplantation. American Journal of Cardiology, 2015, 116, 652-659.	1.6	5
95	Left Ventricular Longitudinal Strain by Speckle-Tracking Echocardiography is Associated With Treatment-Requiring Cardiac Allograft Rejection. Journal of Cardiac Failure, 2014, 20, 359-364.	1.7	58
96	Neutrophil gelatinase-associated lipocalin and cystatin C for the prediction of clinical events in patients with advanced heart failure and after ventricular assist device placement. Journal of Heart and Lung Transplantation, 2014, 33, 1215-1222.	0.6	33
97	Recent Advances in the Diagnosis and Management of Cirrhosis-Associated Cardiomyopathy in Liver Transplant Candidates: Advanced Echo Imaging, Cardiac Biomarkers, and Advanced Heart Failure Therapies. Clinical Medicine Insights: Cardiology, 2014, 8s1, CMC.S15722.	1.8	13
98	Serial Echocardiography Using Tissue Doppler and Speckle Tracking Imaging to Monitor Right Ventricular Failure Before and After Left Ventricular Assist Device Surgery. JACC: Heart Failure, 2013, 1, 216-222.	4.1	90
99	Hepatic Dysfunction in Ambulatory Patients With Heart Failure. Journal of the American College of Cardiology, 2013, 61, 2253-2261.	2.8	145
100	Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system. Journal of Heart and Lung Transplantation, 2012, 31, 601-610.	0.6	154
101	Biomarker-Based Assessment for Infectious Risk Before and After Heart Transplantation. Current Heart Failure Reports, 0, , .	3.3	3